Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '27 | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 13.19 | 21.64 | 19.37 | 13.11 | 15.90 | 18.14 | 21.01 | 21.49 | 16.00 | 16.54 | 17.56 | 18.51 | 14.44 | 13.36 | 14.02 | — | 15.05 | 12.21 | 13.49 | 12.98 | 15.32 |
| — | +19.3% | -7.8% | -39.0% | -0.6% | +9.7% | +19.6% | +16.1% | +10.8% | +23.8% | +25.3% | — | -4.0% | +9.4% | +3.9% | — | -1.7% | -22.5% | +18.0% | -17.6% | +42.3% | |
| P/S Ratio | 1.74 | 1.62 | 2.12 | 2.51 | 2.62 | 2.80 | 3.99 | 3.63 | 3.36 | 3.18 | 3.24 | 3.29 | 2.71 | 2.50 | 2.67 | 2.73 | 2.85 | 2.16 | 2.69 | 2.53 | 2.81 |
| — | -42.1% | -46.9% | -30.8% | -22.2% | -11.8% | +23.1% | +10.1% | +23.9% | +27.1% | +21.3% | +20.8% | -4.8% | +15.5% | -0.8% | +7.9% | +1.3% | -16.1% | +9.8% | +7.9% | +52.4% | |
| P/B Ratio | 1.11 | 1.12 | 1.17 | 1.50 | 1.62 | 1.68 | 2.14 | 2.35 | 2.18 | 2.08 | 2.06 | 2.21 | 1.92 | 1.86 | 2.02 | 2.16 | 1.86 | 1.55 | 1.88 | 1.71 | 2.03 |
| — | -33.4% | -45.3% | -36.2% | -25.7% | -19.1% | +4.1% | +6.4% | +13.9% | +11.6% | +2.2% | +2.3% | +2.9% | +20.6% | +7.1% | +26.0% | -8.5% | -20.7% | +1.0% | +4.3% | +52.7% | |
| P/FCF | 9.50 | 15.94 | 8.39 | 18.78 | 9.85 | 13.88 | 12.73 | 18.44 | 15.36 | 13.30 | 16.13 | 14.31 | 11.04 | 12.03 | 16.00 | 13.82 | 14.78 | 11.35 | 13.04 | 11.25 | 12.05 |
| — | +14.9% | -34.1% | +1.8% | -35.9% | +4.4% | -21.1% | +28.8% | +39.1% | +10.5% | +0.8% | +3.6% | -25.3% | +6.0% | +22.7% | +22.8% | +22.6% | -6.9% | +33.9% | +9.5% | +19.0% | |
| EV / EBITDA | 9.20 | 11.49 | 17.24 | 11.35 | 11.05 | 11.44 | 15.37 | 13.72 | 12.34 | 12.50 | 14.12 | 13.18 | 11.16 | 10.65 | 11.49 | — | 11.81 | 10.60 | 11.65 | 12.16 | 12.77 |
| — | +0.5% | +12.2% | -17.3% | -10.5% | -8.5% | +8.8% | +4.1% | +10.6% | +17.4% | +22.9% | — | -5.5% | +0.5% | -1.4% | — | -7.5% | -17.4% | +13.7% | +2.9% | +26.0% | |
| EV / EBIT | 9.75 | 13.75 | 20.12 | 12.49 | 13.74 | 12.62 | 16.96 | 15.50 | 13.32 | 13.74 | 15.83 | 14.36 | 12.24 | 11.60 | 12.33 | — | 13.08 | 11.74 | 12.90 | 13.57 | 14.04 |
| — | +8.9% | +18.7% | -19.4% | +3.2% | -8.2% | +7.1% | +7.9% | +8.8% | +18.5% | +28.3% | — | -6.4% | -1.2% | -4.4% | — | -6.8% | -19.6% | +16.4% | -13.1% | +26.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '27 | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 51.3% | 51.3% | 50.0% | 55.5% | 56.2% | 54.2% | 59.2% | 55.5% | 55.5% | 54.7% | 54.8% | 55.9% | 55.9% | 55.4% | 53.8% | 54.6% | 55.7% | 57.8% | 55.8% | 56.5% |
| — | -8.7% | -5.4% | -15.5% | +0.1% | +1.3% | -0.9% | +8.0% | -0.7% | -0.7% | -1.3% | +1.9% | +2.3% | +0.4% | -4.2% | -3.5% | -3.4% | -2.5% | -2.2% | -3.3% | -2.9% | |
| Operating Margin | 28.4% | 24.0% | 19.8% | 26.8% | 29.1% | 29.1% | 28.8% | 29.8% | 31.7% | 29.7% | 27.0% | 29.7% | 30.7% | 30.8% | 30.5% | -98.3% | 31.6% | 29.2% | 31.4% | 29.0% | 30.1% |
| — | -17.4% | -31.3% | -10.0% | -8.1% | -2.3% | +6.6% | +0.5% | +3.1% | -3.5% | -11.6% | +130.2% | -2.9% | +5.7% | -2.9% | -438.9% | +5.2% | +2.6% | -7.4% | -2.8% | -2.2% | |
| Net Margin | 17.5% | 7.5% | 11.0% | 19.1% | 16.5% | 15.4% | 19.0% | 16.9% | 21.0% | 19.2% | 18.4% | 17.9% | 18.8% | 18.7% | 19.1% | -84.1% | 18.9% | 17.6% | 19.9% | 19.5% | 18.3% |
| — | -51.2% | -42.3% | +13.4% | -21.6% | -19.7% | +3.6% | -5.4% | +12.1% | +2.5% | -3.7% | +121.2% | -0.5% | +6.1% | -4.4% | -531.2% | +3.1% | +7.5% | -7.0% | +30.6% | +6.9% |
| Metric | TTM | Q2 '27 | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.2% | 1.3% | 1.5% | 2.9% | 2.6% | 2.3% | 2.6% | 2.8% | 3.5% | 3.2% | 2.9% | 3.0% | 3.4% | 3.6% | 3.6% | -15.4% | 3.1% | 3.2% | 3.5% | 3.4% | 3.4% |
| — | -42.9% | -40.4% | +4.9% | -26.3% | -28.0% | -12.6% | -8.9% | +2.5% | -10.3% | -19.2% | +119.8% | +7.6% | +11.5% | +4.1% | -556.2% | -6.8% | +1.1% | -16.0% | +27.0% | +7.3% | |
| ROA | 5.5% | 0.5% | 0.7% | 1.5% | 1.3% | 1.2% | 1.4% | 1.5% | 1.8% | 1.6% | 1.5% | 1.5% | 1.6% | 1.6% | 1.6% | -6.8% | 1.4% | 1.4% | 1.5% | 1.4% | 1.4% |
| — | -55.7% | -48.2% | +2.8% | -26.7% | -25.2% | -6.2% | +0.2% | +15.5% | +2.4% | -6.9% | +121.9% | +13.7% | +15.7% | +5.8% | -576.6% | +2.2% | +10.7% | -9.0% | +38.0% | +15.6% | |
| ROIC | 8.2% | 1.5% | 1.2% | 2.0% | 2.2% | 2.2% | 1.9% | 2.4% | 2.5% | 2.3% | 2.0% | 2.2% | 2.4% | 2.4% | 2.3% | -7.3% | 2.1% | 2.1% | 2.1% | 1.9% | 2.0% |
| — | -29.5% | -40.0% | -17.2% | -11.7% | -5.8% | -1.2% | +6.7% | +5.9% | -4.0% | -15.1% | +130.9% | +10.2% | +15.5% | +8.4% | -482.4% | +5.9% | +3.7% | -11.5% | +1.5% | +4.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '27 | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 1.09 | 1.08 | 0.55 | 0.59 | 0.57 | 0.56 | 0.57 | 0.57 | 0.61 | 0.66 | 0.69 | 0.76 | 0.83 | 0.90 | 0.94 | 0.86 | 0.90 | 0.95 | 0.95 | 1.03 |
| — | +91.4% | +91.6% | -2.7% | +2.7% | -6.9% | -14.4% | -17.4% | -24.2% | -26.5% | -27.3% | -27.1% | -11.7% | -7.8% | -4.7% | -1.1% | -16.6% | -19.0% | -15.1% | -14.4% | -14.2% | |
| Debt / EBITDA | 3.07 | 22.91 | 33.68 | 12.47 | 11.98 | 11.92 | 13.13 | 10.91 | 10.39 | 11.50 | 13.76 | 12.66 | 12.84 | 13.34 | 14.40 | — | 15.19 | 15.80 | 15.72 | 17.53 | 17.23 |
| — | +92.2% | +156.5% | +14.2% | +15.3% | +3.7% | -4.6% | -13.8% | -19.1% | -13.8% | -4.5% | — | -15.4% | -15.6% | -8.4% | — | -11.8% | -16.2% | -1.4% | -9.2% | -11.9% | |
| Current Ratio | 3.57 | 2.92 | 3.23 | 3.57 | 3.11 | 3.70 | 4.38 | 4.20 | 3.68 | 3.56 | 3.23 | 3.20 | 3.09 | 2.99 | 2.66 | 2.44 | 2.55 | 2.21 | 2.09 | 2.04 | 2.04 |
| — | -21.0% | -26.3% | -15.1% | -15.6% | +3.8% | +35.6% | +31.2% | +19.0% | +19.0% | +21.5% | +31.5% | +21.1% | +35.4% | +27.3% | +19.2% | +25.3% | +8.0% | -36.0% | -7.4% | -14.7% | |
| Quick Ratio | 2.25 | 1.86 | 1.99 | 2.25 | 1.93 | 2.51 | 2.99 | 2.82 | 2.20 | 2.10 | 1.90 | 2.02 | 1.92 | 1.75 | 1.51 | 1.43 | 1.56 | 1.29 | 1.23 | 1.21 | 1.25 |
| — | -26.1% | -33.2% | -20.1% | -12.1% | +19.7% | +57.2% | +39.6% | +14.4% | +20.0% | +26.0% | +41.3% | +23.1% | +35.8% | +22.7% | +18.5% | +25.0% | -2.6% | -49.3% | -4.9% | -14.3% | |
| Interest Coverage | 7.08 | 2.58 | 3.76 | 6.67 | 6.79 | 7.89 | 7.05 | 7.87 | 8.00 | 6.84 | 5.45 | 5.41 | 5.20 | 5.00 | 4.88 | -14.78 | 4.80 | 4.92 | 5.64 | 4.82 | 4.87 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PBH stock.
Prestige Consumer Healthcare Inc.'s current P/E is 13.2x. The average P/E over the last 4 quarters is 17.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Prestige Consumer Healthcare Inc.'s current operating margin is 28.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Prestige Consumer Healthcare Inc.'s business trajectory between earnings reports.